3CN3

Human transthyretin (TTR) in complex with 1,3-Dibromo-2-hydroxy-5-phenoxybenzene

Summary for 3CN3

• Entry DOI: 10.2210/pdb3cn3/pdb
• Related: 2QGB 3CN0 3CN1 3CN2 3CN4
• Descriptor: Transthyretin, 2,6-dibromo-4-phenoxyphenol (3 entities in total)
• Functional Keywords: transthyretin, tetramer, hormone, transport protein
• Biological source: Homo sapiens (human)
• Cellular location: Secreted: P02766
• Total number of polymer chains: 2
• Total formula weight: 28242.72

Authors

Connelly, S.,Wilson, I.A. (deposition date: 2008-03-24, release date: 2008-10-28, Last modification date: 2024-02-21)

Primary citation

Johnson, S.M.,Connelly, S.,Wilson, I.A.,Kelly, J.W.
Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies.
J.Med.Chem., 51:6348-6358, 2008

PubMed Abstract: To develop potent and highly selective transthyretin (TTR) amyloidogenesis inhibitors, it is useful to systematically optimize the three substructural elements that compose a typical TTR kinetic stabilizer: the two aryl rings and the linker joining them. Herein, we evaluated 40 bisaryl molecules based on 10 unique linker substructures to determine how these linkages influence inhibitor potency and selectivity. These linkers connect one unsubstituted aromatic ring to either a 3,5-X 2 or a 3,5-X 2-4-OH phenyl substructure (X = Br or CH 3). Coconsideration of amyloid inhibition and ex vivo plasma TTR binding selectivity data reveal that direct connection of the two aryls or linkage through nonpolar E-olefin or -CH 2CH 2- substructures generates the most potent and selective TTR amyloidogenesis inhibitors exhibiting minimal undesirable binding to the thyroid hormone nuclear receptor or the COX-1 enzyme. Five high-resolution TTR.inhibitor crystal structures (1.4-1.8 A) provide insight into why such linkers afford inhibitors with greater potency and selectivity.

PubMed: 18811132
DOI: 10.1021/jm800435s

Experimental method

X-RAY DIFFRACTION (1.8 Å)